4DMedical (ASX:4DX) Tariff Resilience Score: 5/10 (As of Jun. 30, 2026)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.53
GF Value A$1.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical Tariff Resilience Score?

4DMedical ASX:4DX -1.31% 64 Tariff Resilience Score is 5 as of Jun. 30, 2026. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 838 Medical Devices & Instruments companies, 4DMedical ranks better than 79.12% on this metric.

4DMedical has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

4DMedical has 4DMedical relies on specialized medical equipment, which can be subject to tariffs. Its manufacturing is primarily in Australia, with sales in the US and Europe. Historical impacts have been moderate, and the company is exploring alternative suppliers to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes 4DMedical might have Average Resilient.

4DMedical  (ASX:4DX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

4DMedical Tariff Resilience Score Related Terms

ASX:4DX vs ABT, SYK, MDT: Tariff Resilience Score Comparison

For the Medical Devices subindustry, 4DMedical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4DMedical Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 4DMedical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where 4DMedical's Tariff Resilience Score falls into.


ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
4DMedical (ASX:4DX) has a Tariff Resilience Score of 5 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, 4DMedical ranks #175 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 20.9%.
Is 4DMedical's Tariff Resilience Score too high?
4DMedical's current Tariff Resilience Score is 5. Based on the distribution chart, 4DMedical ranks #175 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Tariff Resilience Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 4DMedical ranks #175 out of 838 companies for Tariff Resilience Score. This places 4DMedical in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. 4DMedical's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.53 — trading 214.6% above its estimated fair value. The current Tariff Resilience Score is 5. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current Tariff Resilience Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.53 is trading 214.6% above its estimated GF Value™ of A$1.44. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • Tariff Resilience Score: 5
  • GF Value™: A$1.44 vs. price of A$4.53 (214.6% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.53
Price
A$1.44
GF Value